Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000704899 | SCV000833871 | uncertain significance | Hypertrophic cardiomyopathy 14 | 2024-12-23 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 989 of the MYH6 protein (p.Glu989Lys). This variant is present in population databases (rs369774403, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with MYH6-related conditions. ClinVar contains an entry for this variant (Variation ID: 581153). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt MYH6 protein function with a positive predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ai |
RCV002223243 | SCV002501047 | uncertain significance | not provided | 2022-01-06 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002440533 | SCV002749151 | uncertain significance | Cardiovascular phenotype | 2021-07-16 | criteria provided, single submitter | clinical testing | The c.2965G>A (p.E989K) alteration is located in exon 23 (coding exon 21) of the MYH6 gene. This alteration results from a G to A substitution at nucleotide position 2965, causing the glutamic acid (E) at amino acid position 989 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |